Home › Companies › RAPP

Rapport Therapeutics

RAPP Lead: Phase 3 23 filings & releases ↓ Cash $74.8M (Sep 30, 2026) ↓

Neurology Small Molecule

Market cap $1.45B 59.3M shares (10-Q, Nov 2, 2026) × $24.44 close Nov 6, 2026

Most recent annual filing: 2026-03-10

Pipeline (10 active programs)

RAP-219

Small Molecule Target: TARPγ8, AMPAR, AMPA receptor, TARP γ8

Focal Onset Seizures Phase 3 oral Tenacia Biotechnology
Bipolar Mania Phase 2 oral Tenacia Biotechnology
Undisclosed indication Preclinical subcutaneous Tenacia Biotechnology
Primary Generalized Tonic-Clonic Seizures Phase 2 Tenacia Biotechnology
Undisclosed indication Phase 1 Tenacia Biotechnology
Focal Onset Seizures Phase 1 subcutaneous Tenacia Biotechnology
Focal Onset Seizures intramuscular Tenacia Biotechnology
Bipolar Mania Phase 1 intramuscular

RAP-641

Small Molecule Target: α6β4 nAChR

Technology platforms

RAP technology platform

Precision small molecule drug discovery platform based on receptor associated proteins (RAPs) in the brain, enabling neuroanatomical specificity through selective targeting of RAPs expressed in discrete brain regions; focus on neurological and psychiatric disorders including epilepsy, bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.

Targets: TARPγ8, AMPAR, α6β4 nAChR, α6β4 nicotinic acetylcholine receptor

RAP

Receptor Associated Protein (RAP) technology platform enabling discovery of small molecule precision medicines targeting neuronal receptor complex components for increased selectivity and neuroanatomical specificity; focus areas include epilepsy, psychiatric disorders, chronic pain, migraine, and hearing/vestibular disorders

Targets: TARPγ8, nAChR α6β4, α9α10, AMPAR, nAChR α9α10

RAP Technology Platform · Janssen Pharmaceutical NV

Receptor Associated Protein (RAP) biology platform enabling discovery of precision small molecule neuromedicines. Uses RAPs to unlock previously inaccessible neuronal receptor targets with neuroanatomical specificity. Focus areas: epilepsy, bipolar disorder, chronic pain, migraine, hearing and vestibular disorders, and broader neurological/psychiatric diseases.

Targets: TARP γ8, α6β4 nAChR, α9α10 nAChR

Discontinued (1)

RAP-219 — Diabetic Peripheral Neuropathic Pain · strategic deprioritization in favor of α6β4 program

Capital (as filed)

Cash: $74.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments: $320M Sep 30, 2026
Operating cash flow: −$41.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Filings & releases (23)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

Nov 4, 20268-KCurrent report: results of operations · EX-99.1
Nov 4, 202610-QQuarterly report
Oct 30, 20268-KCurrent report: material agreement, results of operations, debt / obligation
Oct 30, 2026424B5Prospectus supplement (offering)
Oct 30, 2026424B5Prospectus supplement (offering)
Oct 28, 2026FWPFree writing prospectus (offering terms)
Oct 28, 2026FWPFree writing prospectus (offering terms)
Oct 28, 2026FWPFree writing prospectus (offering terms)
Oct 28, 2026FWPFree writing prospectus (offering terms)
Oct 27, 2026424B5Prospectus supplement (offering)
Oct 27, 2026424B5Prospectus supplement (offering)
Oct 20, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
Aug 5, 20268-KCurrent report: results of operations · EX-99.1
Aug 5, 202610-QQuarterly report
Jun 10, 20268-KCurrent report: shareholder vote
May 7, 20268-KCurrent report: results of operations · EX-99.1
May 7, 202610-QQuarterly report
Apr 23, 2026DEFA14AProxy soliciting material
Apr 23, 2026DEF 14AProxy statement
Apr 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
Mar 10, 2026S-3ASRAutomatic shelf registration
Mar 10, 20268-KCurrent report: results of operations · EX-99.1
Mar 10, 202610-KAnnual report

7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)

Oct 29, 2026305B2305B2
Aug 14, 2026SCHEDULE 13G/A13G amendment
Aug 14, 2026SCHEDULE 13G/A13G amendment
Aug 12, 2026SCHEDULE 13G/A13G amendment
May 15, 2026SCHEDULE 13G/A13G amendment
Apr 23, 2026ARSAnnual report to shareholders
Mar 10, 2026S-8Employee plan registration